SCHEMBL830805

SCHEMBL830805

CC(C)Cc1nc(-c2ccc(Cl)cc2)cc(C(F)(F)F)c1C(=O)O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.46
MAPT P10636 2/20 0.46
ALDH1A1 P00352 3/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
ACHE P22303 2/20 0.42
RXFP1 Q9HBX9 1/20 0.42
DHODH Q02127 2/20 0.41
HPGD P15428 3/20 0.41
LMNA P02545 2/20 0.41
MEN1 O00255 1/20 0.41
RAB9A P51151 1/20 0.41
KMT2A Q03164 1/20 0.41
ATM Q13315 1/20 0.41
CTRC Q99895 4/20 0.40
ANO1 Q5XXA6 1/20 0.40
PLA2G1B P04054 1/20 0.39
ATG4B Q9Y4P1 1/20 0.39
KDM4E B2RXH2 2/20 0.39
PSD A5PKW4 1/20 0.39
TSHR P16473 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL829804 0.99 POLB (0.45) POLBMAPTALDH1A1L3MBTL1ACHE
SCHEMBL831045 0.89 DPP4 (0.48) POLBMAPTALDH1A1L3MBTL1ACHE
SCHEMBL829805 0.89 POLB (0.42) POLBMAPTALDH1A1L3MBTL1ACHE
SCHEMBL833856 0.88 L3MBTL1 (0.45) POLBMAPTALDH1A1L3MBTL1ACHE
SCHEMBL831371 0.83 KMO (0.45) ALDH1A1L3MBTL1ACHEDHODHHPGD
SCHEMBL831344 0.82 KMO (0.44) ALDH1A1L3MBTL1ACHEDHODHDPP4
SCHEMBL831342 0.82 KMO (0.44) ALDH1A1L3MBTL1ACHEDHODHHPGD
SCHEMBL832659 0.82 FABP3 (0.46) POLBMAPTALDH1A1L3MBTL1ACHE
SCHEMBL829557 0.81 XDH (0.45) POLBMAPTALDH1A1L3MBTL1ACHE
SCHEMBL831824 0.81 HPGD (0.48) POLBMAPTALDH1A1L3MBTL1ACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143411-B2 Substituted 6-phenylnicotinic acids and their use BAYER ANIMAL HEALTH GMBH (DE) 2012-03-27 US disclosed
US-8143411-B2 Substituted 6-phenylnicotinic acids and their use BAYER ANIMAL HEALTH GMBH (DE) 2012-03-27 US disclosed
US-8143411-B2 Substituted 6-phenylnicotinic acids and their use BAYER ANIMAL HEALTH GMBH (DE) 2012-03-27 US disclosed
US-20100234432-A1 Substituted 6-phenylnicotinic acids and their use BAYER ANIMAL HEALTH GMBH (DE) 2010-09-16 US disclosed
US-20100234432-A1 Substituted 6-phenylnicotinic acids and their use BAYER ANIMAL HEALTH GMBH (DE) 2010-09-16 US disclosed
US-20100234432-A1 Substituted 6-phenylnicotinic acids and their use BAYER ANIMAL HEALTH GMBH (DE) 2010-09-16 US disclosed
WO-2009033561-A1 SUBSTITUTED 6-PHEYLNICOTINIC ACIDS AND THE USE THEREOF BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2009-03-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234432-A1 Substituted 6-phenylnicotinic acids and their use SLC5A6, FABP3, NAPRT POLB 3352/4885MAPT 906/4885ALDH1A1 1238/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.